- Home
- BIOA vs LPTX Comparison
BIOA vs LPTX Comparison
Compare BIOA & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIOA
- LPTX
- Stock Information
- Founded
- BIOA 2015
- LPTX 2011
- Country
- BIOA United States
- LPTX United States
- Employees
- BIOA N/A
- LPTX N/A
- Industry
- BIOA Biotechnology: Pharmaceutical Preparations
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BIOA Health Care
- LPTX Health Care
- Exchange
- BIOA Nasdaq
- LPTX Nasdaq
- Market Cap
- BIOA 139.8M
- LPTX 119.6M
- IPO Year
- BIOA 2024
- LPTX N/A
- Fundamental
- Price
- BIOA $4.05
- LPTX $0.36
- Analyst Decision
- BIOA Hold
- LPTX Buy
- Analyst Count
- BIOA 4
- LPTX 2
- Target Price
- BIOA $5.67
- LPTX $8.00
- AVG Volume (30 Days)
- BIOA 165.9K
- LPTX 272.0K
- Earning Date
- BIOA 05-06-2025
- LPTX 05-13-2025
- Dividend Yield
- BIOA N/A
- LPTX N/A
- EPS Growth
- BIOA N/A
- LPTX N/A
- EPS
- BIOA N/A
- LPTX N/A
- Revenue
- BIOA $1,451,000.00
- LPTX N/A
- Revenue This Year
- BIOA N/A
- LPTX N/A
- Revenue Next Year
- BIOA N/A
- LPTX N/A
- P/E Ratio
- BIOA N/A
- LPTX N/A
- Revenue Growth
- BIOA N/A
- LPTX N/A
- 52 Week Low
- BIOA $2.88
- LPTX $0.22
- 52 Week High
- BIOA $26.62
- LPTX $4.79
- Technical
- Relative Strength Index (RSI)
- BIOA N/A
- LPTX 44.48
- Support Level
- BIOA N/A
- LPTX $0.35
- Resistance Level
- BIOA N/A
- LPTX $0.40
- Average True Range (ATR)
- BIOA 0.00
- LPTX 0.04
- MACD
- BIOA 0.00
- LPTX -0.00
- Stochastic Oscillator
- BIOA 0.00
- LPTX 35.65
About BIOA BioAge Labs Inc. Common Stock
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others.
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .